Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.

The group reports responses with its CD123-targeting ADC, but cash is running short.

Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.

The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.

GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.

The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.

The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

The group is persevering with Granite, but funds might be hard to come by.

First-in-human trial initiations reveal four KRAS assets.